Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: Hepatology. 2019 Oct 11;71(1):334–345. doi: 10.1002/hep.30875

TABLE 1.

Redefining Criteria for CCM

a. World Congress of Gastroenterology Criteria (2005)
Systolic Dysfunction Diastolic Dysfunction Supportive Criteria

Any of the following Any of the following • Electrophysiological abnormalities
• Blunted contractile response on stress testing • Deceleration time >200 milliseconds • Abnormal chronotropic response
• LV ejection fraction <55% • Isovolumetric relaxation time >80 milliseconds • Electromechanical uncoupling
• Prolonged QTc interval
• E/A <1 • Enlarged left atrium
• Increased myocardial mass
• Increased BNP
• Increased proBNP
• Increased troponin I
b. Proposed criteria by the Cirrhotic Cardiomyopathy Consortium (2019)
Systolic Dysfunction Advanced Diastolic Dysfunction Areas for Future Research Which Require Further Validation

Any of the following ≥3 of the following • Abnormal chronotropic or inotropic response§
• LV ejection fraction ≤50% • Septal e′ velocity <7 cm/second • Electrocardiographic changes
• Absolute* GLS <18% • E/e′ ratio ≥15 • Electromechanical uncoupling
• LAVI >34 mL/m2 • Myocardial mass change
• TR velocity > 2.8 m/second • Serum biomarkers
• Chamber enlargement
• CMRI
*

GLS is reported as a negative value in echocardiography reports. Changes in GLS should be described as changes in the absolute value.

Refer to Fig. 3 for echocardiographic changes in early diastolic dysfunction. They were not included in this table given their decreased specificity as they can occur due to aging.

In the absence of evidence of primary pulmonary hypertension or portopulmonary hypertension.

§

Examples include absence of or blunted contractile or diastolic reserve on exercise stress testing, dobutamine stress testing, or at rest on CMRI.

Myocardial extracellular volume as a surrogate for myocardial fibrosis can be assessed using this modality.

Abbreviation: e′, early diastolic mitral annular velocity.

HHS Vulnerability Disclosure